Editorial Review
Author: Dr. Marcus Webb, Ph.D.(Ph.D. Molecular Pharmacology · Science Contributor)|Reviewed by: Scientific Compliance Reviewer
Last reviewed: November 2026
What Closes on November 13, 2026
Quick answer: Comment period closes at 11:59 p.m. ET on November 13, 2026; HHS may then revise, finalize, or drop the draft policy
The two-week public comment period on the Department of Health and Human Services' draft enforcement discretion policy for 503A compounding with six peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon) closes at 11:59 p.m. ET on November 13, 2026 — two weeks after the Federal Register publication on October 30, 2026 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496). The draft policy is a notice of availability of a nonbinding enforcement-discretion statement. The Federal Register notice states the draft policy "does not establish any rights for any person and is not binding on HHS or the public." Key stakeholders including the American Medical Association, Public Citizen, and the American Action Forum submitted comments raising concerns about safety, regulatory precedent, and FDA authority.
The draft policy, summarized in our October 2026 analysis, states HHS does not intend to take enforcement action against state-licensed 503A pharmacies, federal facilities, or licensed physicians compounding with the six peptides—provided they meet specified conditions including: specific peptide forms and routes in Appendix A and B; active pharmaceutical ingredients from FDA-registered cGMP manufacturers with valid certificates of analysis (Appendix B identity, purity, potency, and impurity expectations); single-API products; delivery-device restrictions; labeling including how to report adverse events; and reporting of serious adverse events and product quality issues to FDA and states.
See our October 2026 analysis for full details.
The policy applies only to 503A compounding and does not extend to research-use-only API, compounding that falls outside its conditions, or peptides not listed in Appendix A.
The policy is interim guidance while FDA conducts rulemaking to potentially add these peptides to the official 503A bulks list (21 CFR 216.23).
Holland & Knight noted the policy does not add the peptides to the 503A Bulks List and advised monitoring forthcoming FDA rulemaking.
Important: The comment period closing does not mean the policy is final. HHS may revise the draft, decline to finalize it, or issue a final enforcement discretion statement at a later date. As of November 13, 2026, the draft policy remains nonbinding guidance, and HHS has not announced next steps.
Who Weighed In: Overview of Comment Record
During the two-week comment period, stakeholders submitted comments to the regulations.gov docket. We reviewed comments from three prominent stakeholders whose positions are representative of the broader debate: the American Medical Association (AMA), Public Citizen, and the American Action Forum (AAF). Below is a summary table of their positions, followed by detailed analysis of each comment.
| Stakeholder | Position | Key Arguments | Source |
|---|---|---|---|
| American Medical Association (AMA) | Urge HHS/FDA to immediately rescind the enforcement discretion policy | Unapproved synthetic peptides lack safety, efficacy, and quality evidence; patients at risk of serious harm; substances have not undergone rigorous FDA testing; expanding access without safeguards exposes patients to preventable harm | AMA House of Delegates (I-26), Final Report of Reference Committee K — Resolution 938 adopted; AMA comment letter (Nov 11, 2026) |
| Public Citizen | Urge HHS to reconsider and not implement the policy | FDA scientists recommended against adding each peptide; HHS bypassed FDA and undermined its authority; no adequate safety/efficacy data; says HHS appointed new PCAC members before the July meeting and that without their votes none of the six would have been recommended (PC's characterization); policy sets dangerous regulatory precedent; threatens public health | Public Citizen comment (PDF) submitted Nov 13, 2026 |
| American Action Forum (AAF) | HHS should withdraw the policy; if retained, substantial modifications warranted | Policy undermines narrow regulatory framework; circumvents established 503A bulks list process; patient demand cannot substitute for scientific evidence; risks parallel commercial market; safeguards don't resolve broader uncertainty; no defined expiration | AAF comment submitted Nov 12, 2026 |
Note on comment counts: We are not stating a total number of comments submitted because we did not systematically retrieve and count all docket entries as of a specific date.
The three comments above are representative examples from prominent organizations whose positions are documented in primary sources. Researchers interested in the full comment record should review the regulations.gov docket directly.
American Medical Association: Urge Immediate Rescission
At its November 2026 Interim Meeting (November 6–10, 2026, Orlando, Florida), the AMA adopted Resolution 938 ("Urging Federal Action to Rescind Administrative Directives Permitting Unapproved Synthetic Peptides and Enforce Patient Safety") directing the AMA to take the following actions:
- Urgently advocate to the Department of Health and Human Services, FDA, and relevant federal regulatory authorities to immediately rescind administrative policies, enforcement discretion directives, or policy shifts that ease restrictions on compounding and distributing unapproved, non-FDA-reviewed synthetic peptides, including those for weight loss, wellness, or anti-aging.
- Collaborate with federal agencies, state medical boards, and state boards of pharmacy to enforce strict regulatory oversight and pursue swift enforcement actions against compounding pharmacies, direct-to-consumer telehealth platforms, and online dispensaries distributing unapproved synthetic peptide formulations lacking FDA regulatory review.
- Educate physicians, healthcare providers, and the public regarding the severe safety risks, lack of clinical efficacy, and lack of FDA oversight associated with unapproved synthetic peptide compounds and multipeptide "stacks."
According to the AMA press release, AMA Board Member Ilse R. Levin, DO, MPH & TM stated:
AMA Board Member Statement
"By allowing pharmacies to compound unapproved synthetic peptide substances without sufficient evidence of their safety and efficacy, patients are at increased risk of serious harm. These substances have not undergone the rigorous testing required of FDA-approved drugs, and expanding access without adequate safeguards and oversight could expose patients to serious, preventable harm," Levin said. "We are committed to making sure physicians, other healthcare professionals, and the public are aware of the severe safety risks, lack of clinical data on efficacy, and lack of FDA oversight associated with unapproved synthetic peptide compounds."
In a November 11, 2026 comment letter to HHS (signed by AMA CEO John Whyte, MD, MPH), the AMA urged HHS to rescind the policy, stating: "The AMA opposes the HHS non-enforcement policy and urges HHS to rescind the policy in favor of having the substances' efficacy and safety undergo the full FDA review process.
" The letter further stated: "Allowing these substances to be used in compounded formulations exposes patients to unnecessary risks and undermines confidence in the evidence-based standards that guide drug evaluation and approval. "
The AMA's November 13, 2026 National Advocacy Update confirmed the AMA sent the letter urging rescission of the proposed "non-enforcement" policy.
What the AMA's Position Means
The AMA policy is significant because it reflects organized medicine's institutional view that the HHS enforcement discretion policy threatens patient safety. The AMA's policies are developed through a deliberative process involving state and specialty society delegates. The policy's adoption signals that physician leaders view the HHS enforcement discretion policy as inconsistent with evidence-based drug evaluation standards.
The AMA did not endorse the policy with additional safeguards. It called for rescission — meaning HHS should withdraw the policy entirely. This is a stronger position than requesting modifications or a shorter duration.
Free Peptide Calculator
Calculate precise reconstitution volumes and dosages with our peptide calculator tool.
Public Citizen: Policy Bypasses FDA and Threatens Public Health
Public Citizen, a national nonprofit consumer advocacy organization with over one million members and supporters, submitted a comment (PDF) on November 13, 2026, urging HHS to reconsider and not implement the enforcement discretion policy. Public Citizen's comment raises several concerns:
1. FDA Scientists Recommended Against Adding the Peptides
Public Citizen states that "FDA scientists recommended against adding each of the peptides to the 503A bulks list (that would allow the substances to be compounded), due to a lack of adequate data on the efficacy and safety of these substances.
" This refers to the July 2026 PCAC meeting, where FDA's Center for Drug Evaluation and Research (CDER) staff presented briefing materials recommending against inclusion.
2. PCAC Committee Appointments
Public Citizen alleges that "Just prior the meeting, HHS appointed new PCAC members who were predisposed to add the six peptides to the 503A bulks list.
By appointing the new members, HHS cleared the way for the committee to make the recommendations the department desired. Without the votes of the newly appointed members, none of the six peptides would have been recommended. "
Public Citizen links to its own July 23, 2026 press release as supporting documentation. We note that Public Citizen's characterization of the PCAC appointments and vote outcomes is Public Citizen's own interpretation. The PCAC vote was advisory and nonbinding.
3. HHS Bypassed FDA and Undermined FDA Authority
Public Citizen states: "To date, the FDA has not announced its decision about whether to add any of the peptides to the 503A bulks list.
However, with its announcement of the enforcement discretion policy, the HHS effectively bypassed the FDA and its decision-making process.
HHS has thus not only undermined the FDA's authority to halt the marketing and sale of unapproved drugs but also set a dangerous regulatory precedent that threatens public health and puts patients at risk. "
4. Lack of Adequate Safety and Efficacy Data
Public Citizen argues that "Peptides, like any other investigational drug, should go through the standard FDA approval process for new drugs and not be made available to the public because 'HHS believes that there is significant interest in the use of these peptides in compounding' or because it 'advances patient choice and freedom.
'" Public Citizen further states: "Since there are no adequate data yet on the safety and efficacy for these six peptides, Public Citizen also strongly disagrees that the enforcement discretion policy is 'appropriately protecting patient safety. '"
5. Call for Vigorous FDA Enforcement
Public Citizen concludes: "Instead of this flawed enforcement discretion policy, which may put patients at risk, HHS should support vigorous FDA enforcement of regulations to prohibit the manufacture, distribution, and marketing of both research-use-only peptides and other unapproved peptides."
Public Citizen's Core Argument
HHS circumvented the FDA's ongoing evaluation process by issuing enforcement discretion before FDA completed its review. According to Public Citizen, this undermines FDA's authority to regulate unapproved drugs and creates a dangerous precedent where patient interest and choice—rather than safety and efficacy evidence—drive drug availability.
Public Citizen's comment was submitted by Nina Zeldes, Ph.D., Senior Health Researcher, Health Research Group, Public Citizen, on November 13, 2026.
Get Peptide Research Updates
New research, product launches, and exclusive offers. No spam.
American Action Forum: Circumventing the Regulatory Framework
The American Action Forum (AAF), a 21st century center-right policy institute, submitted a detailed comment on November 12, 2026.
AAF's comment does not call for immediate rescission but recommends that "HHS should withdraw the October 30 enforcement discretion policy until FDA completes individual safety and efficacy assessments of the six substances.
" If HHS elects to maintain enforcement discretion, AAF proposes substantial modifications. Below are AAF's key arguments:
1. Policy Undermines the Narrow Regulatory Framework
AAF argues that "The October 30 policy undermines this narrow regulatory framework." Congress established Section 503A compounding exemptions for individualized medications when commercially available products cannot meet a patient's clinical needs (e.g., allergies to specific ingredients). Those exemptions were not designed to create a substitute for FDA's drug approval process or to allow distributing unapproved products.
AAF notes that Section 503A provides a process for determining eligibility of bulk substances through inclusion on the 503A bulks list, requiring scientific evaluation, consultation with PCAC, and rulemaking. "The six peptides identified in the October 30 policy have not completed this process.
" According to AAF, although the policy does not formally add the peptides to the bulks list, its practical effect is to permit their distribution under conditions resembling those ordinarily available to qualifying Section 503A preparations.
2. Patient Demand Cannot Substitute for Scientific Evidence
AAF addresses HHS's justifications for the policy, which cite additional information regarding historical utilization, product characterization data, and clinical experience. AAF argues that these considerations are relevant but do not resolve the underlying scientific questions.
- Historical utilization is not evidence of clinical effectiveness: The fact that a substance has been compounded or administered to patients does not establish that it produces a clinically meaningful benefit.
- Absence of documented adverse events should not be mistaken for affirmative evidence of safety: Limited clinical exposure, inadequate long-term follow-up, and incomplete adverse event reporting can make uncommon or delayed risks difficult to identify.
- Improvements in product characterization should be distinguished from evidence concerning clinical use: Certificates of analysis can materially improve confidence in the quality of bulk ingredients. They do not, however, establish the appropriate dosage, duration of treatment, potential long-term risks, or effectiveness of a compounded preparation.
AAF concludes: "The concern is that HHS is expanding access before the required balancing process has reached its conclusion."
3. Risk of Parallel Commercial Market for Unapproved Drugs
AAF notes that early commercial responses to the HHS announcement suggest enforcement discretion could support substantial commercial distribution networks.
AAF cites Enhanced's November 3 announcement that it had begun offering all six peptides through its telehealth platform, and Hims & Hers' announced plans for a peptide-focused business including potential future access to BPC-157 and TB-500.
AAF states: "Such responses raise broader questions about the incentives created by the policy. If a company can develop a substantial market for an unapproved drug through compounding, its incentives to pursue traditional pharmaceutical development may be diminished. "
4. Safeguards Do Not Fully Address the Policy's Shortcomings
AAF acknowledges the 10 conditions HHS imposed are meaningful safeguards but argues "these requirements principally address identifiable quality and distribution risks. They do not resolve the broader uncertainty regarding whether the six substances are appropriate for expanded clinical use."
AAF notes that the policy does not establish a defined calendar-based expiration date. "That approach creates uncertainty regarding how long the policy may operate and what circumstances would warrant its modification or termination. A policy described as interim should not be permitted to function indefinitely simply because the underlying rulemaking remains incomplete."
AAF's Recommendations
If HHS maintains enforcement discretion, AAF recommends:
- Establish a defined duration and transparent termination criteria: Include a fixed expiration date; an extension should require documented justification addressing continued clinical need, updated scientific evidence, and adequacy of existing safeguards.
- Require a clear, substance-specific scientific justification: Publish an assessment addressing the evidence supporting each peptide and permitted route of administration, including the rationale for departing from CDER's recommendations.
- Strengthen oversight of commercial distribution practices: Closely evaluate arrangements that facilitate large-scale prescribing and distribution, particularly those involving telehealth intermediaries and standardized treatment protocols.
AAF's comment was submitted by Michael Baker and Douglas Holtz-Eakin on November 12, 2026.
Important Disclaimer
All products and information on this page are intended strictly for laboratory and scientific research use only. Not for human consumption. These statements have not been evaluated by the FDA.
What the Comments Reveal: Three Perspectives on Safety, Authority, and Process
The three comments we reviewed reflect distinct but overlapping concerns about the HHS enforcement discretion policy:
| Theme | AMA | Public Citizen | American Action Forum |
|---|---|---|---|
| Patient Safety | Patients at risk of serious harm; substances lack rigorous FDA testing | No adequate safety/efficacy data; threatens public health | Historical use and absence of documented adverse events do not establish safety; broader uncertainty remains unresolved |
| FDA Authority | Undermines evidence-based standards that guide drug evaluation and approval | HHS bypassed FDA and undermined FDA's authority to halt marketing of unapproved drugs; sets dangerous regulatory precedent | Policy circumvents established 503A bulks list process; enforcement discretion precedes completion of regulatory evaluation process |
| Regulatory Process | Lack of FDA review and approval | FDA scientists recommended against adding each peptide; HHS issued policy before FDA completed its review | Policy risks diminishing significance of eventual regulatory determination; patient demand cannot substitute for scientific evidence; no defined expiration |
| Commercial Distribution | Enforcement actions needed against compounding pharmacies, telehealth platforms, and online dispensaries distributing unapproved peptides | Vigorous FDA enforcement needed to prohibit manufacture, distribution, and marketing of research-use-only peptides and other unapproved peptides | Policy risks parallel commercial market; compounding could become enduring pathway for drugs broadly marketed without completing regulatory process; strengthen oversight of telehealth intermediaries and standardized protocols |
Common ground: All three stakeholders express concerns about safety evidence, the process by which HHS issued the policy, and the potential for expanded distribution of unapproved drugs.
The AMA calls for rescission and Public Citizen urges HHS to reconsider and not implement the policy; AAF recommends withdrawal or, if maintained, substantial modifications including a defined expiration date and substance-specific scientific justifications.
Points of divergence: Public Citizen's comment is the most critical of the PCAC vote process itself, stating that HHS appointed new PCAC members just before the July meeting and that without their votes none of the six would have been recommended, and arguing HHS undermined FDA's authority.
AAF does not allege impropriety in the PCAC process but focuses on the policy's practical effects and the precedent it sets for future enforcement discretion.
The AMA's resolution is broader, addressing unapproved synthetic peptides generally (not only the six covered by HHS's October 2026 policy) and calling for public education campaigns.
How This Fits with the USP November 3, 2026 Statement
The public comments align with the concerns the United States Pharmacopeia (USP) raised in its November 3, 2026 statement on the HHS enforcement discretion policy.
USP stated that the policy does not include essential safeguards needed to ensure quality and safety: the six peptides do not have USP-NF monographs, USP reference standards, or established bulk drug substance names (USAN, INN, IUPAC) that define their identity and substance-specific quality attributes.
USP's concerns were about quality infrastructure: without monographs and reference standards, the quality of the bulk drug substance cannot be reliably and consistently established. The AMA, Public Citizen, and AAF comments broaden the critique to safety, efficacy, and regulatory process:
- USP: No quality infrastructure (monographs, reference standards, official names) → COAs alone cannot ensure consistent quality.
- AMA / Public Citizen / AAF: No adequate safety/efficacy data, FDA scientists recommended against inclusion, and HHS bypassed the established regulatory process → enforcement discretion exposes patients to risks and undermines FDA authority.
Together, the USP statement and the stakeholder comments form a multi-layered critique of the policy: concerns about quality assurance (USP), safety and efficacy evidence (AMA, Public Citizen, AAF), and regulatory process and precedent (Public Citizen, AAF).
What Happens Next: HHS May Revise, Finalize, or Decline to Implement
Once the comment period closes at 11:59 p.m. ET on November 13, 2026, HHS may take several paths:
1. Revise the Draft Policy
HHS may revise the draft enforcement discretion policy in response to comments. Potential revisions could include:
- Defined expiration date: AAF recommended a fixed expiration date and transparent termination criteria. HHS could add a sunset provision, requiring the policy to expire by a specific date unless extended with documented justification.
- Substance-specific scientific justification: HHS could publish an assessment addressing the evidence supporting each peptide and permitted route of administration, including the rationale for departing from FDA CDER's recommendations, as AAF suggested.
- Stricter oversight of commercial distribution: HHS or FDA could clarify how they will oversee telehealth-driven prescribing arrangements and large-scale compounding operations to distinguish traditional patient-specific compounding from commercial distribution.
- Additional quality safeguards: In response to USP's statement, HHS could require compounders to use only bulk drug substances from manufacturers that provide documentation of reference standard traceability or third-party testing.
2. Finalize the Policy as Drafted
HHS may finalize the draft policy without changes. The Federal Register notice states the draft policy "is not binding on HHS or the public," and HHS "may revisit application of this interim policy (in whole or in part)." However, finalizing the policy as drafted would leave the concerns raised by the AMA, Public Citizen, AAF, and USP unaddressed.
3. Decline to Implement (Rescind the Draft)
HHS may decide not to implement the enforcement discretion policy at all, effectively rescinding the draft. This would align with the AMA's and Public Citizen's requests. If HHS declines to implement the policy, compounding with the six peptides would remain unauthorized under 503A unless and until FDA completes rulemaking and adds them to the official 503A bulks list.
4. Await FDA Rulemaking on the 503A Bulks List
The enforcement discretion policy is an interim measure while FDA conducts rulemaking to potentially add these peptides to the official 503A bulks list (21 CFR 216.23). According to Holland & Knight legal analysis, the policy does not add these peptides to the 503A Bulks List; H&K advises readers to monitor forthcoming FDA rulemaking.
If FDA proposes to add any of the six peptides to the 503A bulks list through formal rulemaking, that proposal will include a separate Federal Register notice and comment period.
At that stage, the concerns raised in the current comment record would likely be raised again—and FDA would need to address how safety and quality will be assured, or announce plans to develop USP monographs and reference standards.
5. State Boards May Differ
The HHS enforcement discretion policy states HHS does not intend to take federal enforcement action. It does not bind state boards of pharmacy or state medical boards. Some states may choose to enforce stricter standards or prohibit compounding with these peptides even if HHS declines federal enforcement. Compounders and prescribers should consult state-specific guidance.
Timeline: HHS has not announced a timeline for next steps. As of November 13, 2026, the draft policy remains nonbinding guidance, and HHS has not indicated when it will finalize, revise, or rescind the policy.
What This Means for Research-Use-Only (RUO) Procurement
The HHS enforcement discretion policy and the public comment record apply to 503A compounding pharmacy practice, not to research-use-only catalog suppliers selling peptides for laboratory and analytical use. However, several themes from the comment record are relevant to RUO procurement:
1. Quality Infrastructure Gaps (USP and AAF)
USP noted that the six peptides lack USP-NF monographs, USP reference standards, and established names. AAF noted that improvements in product characterization (certificates of analysis) should be distinguished from evidence concerning clinical use. Laboratories sourcing peptides for research should ask suppliers:
- What reference standard was used for identity and purity testing?
- Is that reference standard traceable to a recognized authority (USP, NIST) or is it an in-house standard?
- What acceptance criteria were applied (not just "≥98% purity," but what method and what threshold)?
- Can you provide the full analytical report, not just the summary COA?
See our guides on how to read a peptide COA and how to verify COA authenticity for detailed checklists.
2. Safety Data Gaps (AMA, Public Citizen, AAF)
All three stakeholder comments emphasize the lack of adequate safety and efficacy data for the six peptides. Laboratories working with these materials should follow institutional biosafety and chemical handling protocols, document procurement and protocol approvals, and maintain clear RUO labeling and storage records. See our RUO documentation checklist.
3. Vigorous FDA Enforcement (Public Citizen)
Public Citizen called for "vigorous FDA enforcement of regulations to prohibit the manufacture, distribution, and marketing of both research-use-only peptides and other unapproved peptides. " This signals that advocacy groups may urge FDA to scrutinize RUO suppliers more closely.
In an August 24, 2026 warning letter to NuScience Peptides LLC, FDA stated that despite product labeling marketing the products "for laboratory, research, and analytical use" and "not intended for human or veterinary use," evidence from the company's website established that the products were intended to be drugs for human use.
RUO suppliers and laboratory procurement teams should ensure suppliers maintain clear RUO positioning, do not make therapeutic claims, provide batch-specific COA documentation, and focus on institutional customers. The regulatory landscape for peptides is evolving rapidly; laboratories should stay informed and document procurement decisions carefully.
Internal Links: Related Analysis and Resources
This post builds on our prior regulatory analysis. For a complete picture of the HHS enforcement discretion policy, the USP statement, and the broader regulatory timeline, see:
- HHS Peptide Enforcement Discretion Policy (Oct 2026) — Full Analysis
- USP Statement on HHS Peptide Policy: Quality Standards Gap for 503A Compounding
- FDA's Next Peptide Panel: LL-37, GHK-Cu, Dihexa, Melanotan II & PEG-MGF
- Research Peptide Regulatory Timeline (2023–2026)
- FDA Peptide Reclassification 2026 — Complete Timeline
For the six peptides covered by the HHS policy, see our compound research pages:
- BPC-157 Research Page
- TB-500 Research Page
- KPV Research Page
- MOTS-c Research Page
- Semax Research Page
- Epitalon Research Page
For quality assurance and procurement guidance, see:
Sources and References
All claims in this analysis are sourced from primary Federal Register documents, public comments submitted to the regulations.gov docket, and official organizational statements. Below is the complete source list:
- Federal Register Notice (October 30, 2026): Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, 91 FR 68526-68527. https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
- Public Comment Docket: https://www.regulations.gov/docket/HHS-OASH-2026-0496
- AMA policy adopted at the 2026 Interim Meeting (Nov 6–10, 2026): AMA House of Delegates (I-26), Final Report of Reference Committee K. https://www.ama-assn.org/system/files/i26-refcomm-k-annotated.pdf
- AMA Highlights from the 2026 AMA Interim Meeting: https://www.ama-assn.org/house-delegates/interim-meeting/highlights-2026-ama-interim-meeting
- AMA Press Release (November 2026): "AMA adopts new policies to protect patients and strengthen public health." https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policies-protect-patients-and-strengthen-public
- AMA Comment Letter (November 11, 2026): American Medical Association letter to Victoria Marshall, Department of Health and Human Services, signed by John Whyte, MD, MPH, "Re: Docket No. HHS-OASH-2026-0496." https://searchlf.ama-assn.org/letter/documentDownload?uri=/unstructured/binary/letter/LETTERS/lfb.zip/2026-11-11-Letter-to-Marshall-re-Peptide-Policy-v2.pdf
- AMA National Advocacy Update (November 13, 2026): https://www.ama-assn.org/health-care-advocacy/advocacy-update/nov-13-2026-national-advocacy-update
- Public Citizen Comment (November 13, 2026): Nina Zeldes, Ph.D., "Comments on the Department of Health and Human Services' Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (HHS-OASH-2026-0496)." https://www.citizen.org/wp-content/uploads/2815.pdf
- American Action Forum Comment (November 12, 2026): Michael Baker and Douglas Holtz-Eakin, "Comments to HHS on Enforcement Discretion Policy Regarding 503A Peptide Compounding." https://www.americanactionforum.org/comments-for-record/comments-to-hhs-regarding-peptide-compounding/
- USP Statement (November 3, 2026): United States Pharmacopeia, "USP statement on quality and safety considerations for unapproved peptides." https://www.usp.org/news/usp-statement-on-quality-and-safety-considerations-for-unapproved-peptides
- Holland & Knight Legal Alert (November 4, 2026): Sara M. Klock, Michael J. Werner, Sarah Starling Crossan, Andrew I. Namkung, "HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides." https://www.hklaw.com/en/insights/publications/2026/11/hhs-issues-interim-enforcement-discretion-policy-for-compounding
- FDA Warning Letter (August 24, 2026): U.S. Food and Drug Administration, "Warning Letter: NuScience Peptides LLC 733652." https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
- Federal Food, Drug, and Cosmetic Act, Section 503A: 21 U.S.C. § 353a.
- 21 CFR 216.23 (503A Bulks List): U.S. Electronic Code of Federal Regulations, title 21, chapter I, subchapter C, part 216, subpart B, section 216.23. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
Important Disclaimer — For Research Use Only
The information provided is for educational and research purposes only. All peptides discussed or linked on this site are intended strictly for laboratory and scientific research use only (RUO) and are not for human consumption, injection, ingestion, or any therapeutic application. These products have not been evaluated or approved by the FDA or any regulatory body and are not intended to diagnose, treat, cure, or prevent any disease or condition. Reliance on this content is at your own risk. Consult qualified professionals for any health-related decisions. PurePep Vital disclaims all liability for misuse. Products are offered by third-party retailers for research use only.
PurePep Vital is an editorial publisher, vendor comparison resource, and affiliate deal tracker. We do not manufacture, compound, sell, ship, test, prescribe, or handle peptide products. Purchases are completed directly through third-party retailers. PurePep Vital is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. PurePep Vital is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.
Need deals after the research?
Use the deals hub to compare current offers, partner codes, and research news. We recommend retailers that provide quality signals when available.
Explore Our Guides
Related Articles

HHS Files Peptide Enforcement Discretion Policy for 503A Compounding — Oct 2026
On October 28, 2026, HHS filed a Federal Register notice announcing enforcement discretion for state-licensed pharmacies, federal facilities, and physicians compounding with certain peptides including BPC-157 and TB-500. Here is what the policy covers, what it does not, and the timeline ahead.

USP Statement on HHS Peptide Policy: Quality Standards Gap for 503A Compounding
On November 3, 2026, the United States Pharmacopeia (USP) issued a public statement on the HHS enforcement discretion policy for six peptides (BPC-157, TB-500, others), stating it lacks essential quality safeguards: no USP-NF monographs, no reference standards, and no established names. Here is what USP said and why it matters for identity and purity testing.

FDA's Next Peptide Panel: LL-37, GHK-Cu, Dihexa, Melanotan II & PEG-MGF
FDA will convene the Pharmacy Compounding Advisory Committee before the end of February 2027 to discuss five bulk drug substances for possible inclusion on the 503A bulks list: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF. Here is what the meeting can and cannot decide, how it relates to the July 2026 PCAC and October 2026 HHS policy, and FDA's published safety concerns for each substance.

BPC-157 and TB-500 Stack: What the Recovery Research Actually Shows
BPC-157 and TB-500 are the two most-paired peptides in tissue-repair research. This guide explains why their mechanisms are studied together, what the preclinical literature supports, and how laboratories evaluate documentation before sourcing.
Frequently Asked Questions
The two-week public comment period on HHS's draft enforcement discretion policy for 503A compounding with six peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon) closes at 11:59 p.m. ET on November 13, 2026 — two weeks after the Federal Register publication on October 30, 2026 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496). The Federal Register notice states the draft policy "does not establish any rights for any person and is not binding on HHS or the public."